Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

49.65 -0.35 (-0.70%)
Streaming Delayed Price Updated: 12:15 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,851,947
Open 50.10
Bid (Size) 49.65 (2)
Ask (Size) 49.66 (6)
Prev. Close 50.00
Today's Range 49.22 - 50.40
52wk Range 39.35 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 4.83%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns. 
Via Benzinga
Which S&P500 stocks are moving on Tuesday?
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill

Performance

YTD
-12.6%
-12.6%
1 Month
-17.2%
-17.2%
3 Month
-10.9%
-10.9%
6 Month
-5.9%
-5.9%
1 Year
+2.4%
+2.4%

More News

Read More
What's going on in today's session: S&P500 gap up and gap down stocks
Via Chartmill
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
Via Investor's Business Daily
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
From Bristol Myers Squibb
Via Business Wire
These Large-Cap Stocks With China And EU Exposure Got Crushed In The One Of The Most Volatile Trading Week (Apr 7-Apr 11): Are These In Your Portfolio?
Via Benzinga
Topics World Trade
Exposures Tariff
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock.
Via Chartmill
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Via Benzinga
3 Value Stocks in the Doghouse
Via StockStory
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Via Benzinga
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
What's going on in today's session: S&P500 movers
Via Chartmill
These S&P500 stocks are gapping in today's session
Via Chartmill
Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday?
Via Benzinga
Topics World Trade
Exposures Tariff
FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients
Via Benzinga
Exposures Product Safety
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Bristol Myers Wins Dismissal Of Class Action Lawsuit Accusing It Of Fraudulently Acquiring Patents – Retail Sentiment Remains Subdued
Via Stocktwits
Topics Fraud Government Intellectual Property
Exposures Financial Intellectual Property Legal
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer1
From Bristol Myers Squibb
Via Business Wire
Is Pfizer Stock a Buy?
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Laser-Focus on These Tariff-Proof Stocks Before It’s Too Late
Via InvestorPlace
Topics Government Intellectual Property World Trade
Exposures Intellectual Property Political Tariff
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 49.65
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 04/16/25 12:15 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 110.33B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 110B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.